CRTX.LSE CRISM Therapeutics Corporation

Healthcare Biotechnology London Exchange
0.0875 GBX
Close of Oct 24, 2026
8.00 18.50
Market cap
GBX 6.97M
P/E
-
P/B
2.70x
ROE
-219.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CRTX.LSE undervalued?

Graham number

The Graham number of CRISM Therapeutics Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CRISM Therapeutics Corporation fundamental analysis

No fundamental analysis for CRISM Therapeutics Corporation yet.

CRISM Therapeutics Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation an…

Full company profile